index	sentence	Gene	Disease	prediction
0	Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine	K-Ras	colorectal tumours	1
1	Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine	K-Ras	cancer	1
2	Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status	EGFR	colorectal cancer	0
3	Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status	Kirsten-Ras	colorectal cancer	1
4	Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status	K-Ras	colorectal cancer	0
5	Colorectal tumours (n=106) were screened for additional K-Ras mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis	K-Ras	Colorectal tumours	1
6	Colorectal tumours (n=106) were screened for additional K-Ras mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis	K-Ras	Colorectal tumours	1
7	Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified	K-Ras	tumours	1
8	We additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumours.	K-Ras	tumours	1
9	The identification of mutations outwith previously described hotspot codons increases the K-Ras mutation burden in colorectal tumours by one-third	K-Ras	colorectal tumours	1
10	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	colorectal cancer	1
11	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	colorectal cancer	1
12	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	colorectal cancer	1
13	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	tumour	1
14	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	tumour	1
15	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	tumour	1
16	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	adenomatous polyposis coli	1
17	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	adenomatous polyposis coli	1
18	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	adenomatous polyposis coli	1
19	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	APC	1
20	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	APC	1
21	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	APC	1
22	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	p53	adenoma-carcinoma	1
23	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	Kirsten-Ras	adenoma-carcinoma	1
24	A genetic model for colorectal cancer highlighted key genes, including the tumour suppressor genes adenomatous polyposis coli (APC) and p53 and the oncogene Kirsten-Ras (K-Ras), the progressive acquisition of mutations in which was proposed to regulate the adenoma-carcinoma transition (Vogelstein et al, 1988)	K-Ras	adenoma-carcinoma	1
25	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	Dukes' C tumours	1
26	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	tumour	1
27	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	Dukes' C tumours	1
28	We subsequently refined this model (Smith et al, 2002), highlighting a significant increase in K-Ras mutation frequency in Dukes' C tumours, suggesting that K-Ras mutation status may be an important determinant of tumour progression	K-Ras	tumour	1
29	We additionally used comparative genomic hybridisation (CGH) analysis to identify common chromosomal aberrations in colorectal tumours, and highlighted an amplification of the region of chromosome 12p where the K-Ras gene is localised (Leslie et al, 2003)	K-Ras	colorectal tumours	1
30	We and others have shown that K-Ras mutations are associated with significantly reduced survival in colorectal cancer patients (Andreyev et al, 2001; Conlin et al, 2005), although previous data is not entirely consistent (Etienne-Grimaldi et al, 2008; Winder et al, 2009)	K-Ras	colorectal cancer	0
31	K-Ras mutation status has recently been convincingly associated with response to the new generation EGFR antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt K-Ras tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009)	K-Ras	K-Ras tumours	1
32	K-Ras mutation status has recently been convincingly associated with response to the new generation EGFR antagonists cetuximab (Erbitux) and panitumumab (Vectibix), where response is preferentially observed in wt K-Ras tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009)	EGFR	K-Ras tumours	1
33	K-Ras mutation testing is therefore increasingly recommended to facilitate selection of the most appropriate patients for treatment with EGFR antagonists (McNeill, 2008; van Krieken and Tol, 2009).	K-Ras	van Krieken	1
34	K-Ras mutation testing is therefore increasingly recommended to facilitate selection of the most appropriate patients for treatment with EGFR antagonists (McNeill, 2008; van Krieken and Tol, 2009).	EGFR	van Krieken	1
35	Previous analyses of K-Ras mutations in human tumours have consistently focussed on single-point mutations in codons 12, 13 and 61, where mutation has been shown to result in reduced Ras GAP GTPase activity, locking the protein in the active Ras-GTP conformation (Ellis and Clark, 2000), although additional mutations at codons 19, 22 and 146 have been described in single colorectal tumour case reports (Orita et al, 1991; Miyakura et al, 2002; Akagi et al, 2007).	K-Ras	tumours	1
36	Previous analyses of K-Ras mutations in human tumours have consistently focussed on single-point mutations in codons 12, 13 and 61, where mutation has been shown to result in reduced Ras GAP GTPase activity, locking the protein in the active Ras-GTP conformation (Ellis and Clark, 2000), although additional mutations at codons 19, 22 and 146 have been described in single colorectal tumour case reports (Orita et al, 1991; Miyakura et al, 2002; Akagi et al, 2007).	K-Ras	colorectal tumour	1
37	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	cancers	0
38	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	melanoma	0
39	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	ovarian and colorectal tumours	0
40	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	colorectal tumours	0
41	B-Raf mutations have also been identified in human cancers, including melanoma and thyroid, ovarian and colorectal tumours, although mutation frequency estimates in colorectal tumours vary from 1 to 20%, and have been particularly associated with tumours deficient in mismatch-repair activity (Wellbrock et al, 2004)	B-Raf	tumours deficient	0
42	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	tumours	1
43	The most common B-Raf mutation is a T to A transversion, resulting in a valine to glutamic acid substitution (V600E), present in approximately 90% of B-Raf mutant tumours (Davies et al, 2002), which results in a 500-fold increase in in vitro kinase activity and the induction of cell proliferation and transformation (Wan et al, 2004)	B-Raf	tumours	0
44	Although K-Ras and B-Raf mutations are found in the same tumour types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways	K-Ras	tumour	1
45	Although K-Ras and B-Raf mutations are found in the same tumour types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways	B-Raf	tumour	1
46	Although K-Ras and B-Raf mutations are found in the same tumour types, they are thought to be mutually exclusive (Wellbrock et al, 2004), providing distinct but related mechanisms for the activation of K-Ras signalling pathways	K-Ras	tumour	1
47	B-Raf mutation status has also recently been associated with response to cetuximab and panitumumab where, like K-Ras, clinical response is limited to wt B-Raf tumours (Di Nicolantonio et al, 2008).	B-Raf	B-Raf tumours	1
48	B-Raf mutation status has also recently been associated with response to cetuximab and panitumumab where, like K-Ras, clinical response is limited to wt B-Raf tumours (Di Nicolantonio et al, 2008).	K-Ras	B-Raf tumours	1
49	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	colorectal tumours	0
50	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	tumour	0
51	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	EGFR	colorectal tumours	0
52	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	colorectal tumours	0
53	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	EGFR	tumour	0
54	As K-Ras mutations in colorectal tumours are clearly important biomarkers of tumour progression and patient survival and also influence response to new generation EGFR antagonists, we have used a variety of experimental approaches to further investigate inter-individual differences in K-Ras mutation burden.	K-Ras	tumour	0
55	K-Ras was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).	K-Ras	tumour	1
56	K-Ras was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).	K-Ras	tumour	1
57	K-Ras was amplified from genomic DNA extracted from normal and tumour tissues (n=96 normal/tumour pairs) from our colorectal patient series (Smith et al, 2002) with the oligonucleotide primers 5'-TTTAATACTTTTTATGTATTTCAGGGTGTTG-3' (300 nM) and 5'-TTACCATCTTTGCTCATCTTTTCTTTAT-3' (300 nM) and Taqman probe 5'-FAM-TGATGCCTTCTATACATTAGTTCGAGAAATTCGAAAA-TAMRA-3' (100 nM), and expression compared with RNAse P by the comparative Ct method, according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).	K-Ras	colorectal	1
58	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1
59	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1
60	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1
61	Meanwhile, 1 mul chromosome 12p BAC RP11-707G18 (Red) (BlueGnome), 1 mul chromosome 12q BAC RP11-89H19 (Green) (BlueGnome) and 9 mul LSI-WCP hybridisation buffer (Vysis) was mixed together for each slide and pipetted onto a 22 x 22 mm coverslip which was placed onto a region of the slide containing tumour tissue and placed onto a heat block at 75 C for 5 min to co-denature the probes and tumour tissue	RP11	tumour	1
62	We have previously described K-Ras mutations at codons 12, 13 and 61 in a series of 106 unselected colorectal tumours (Smith et al, 2002)	K-Ras	colorectal tumours	0
63	Mutations at codon 19 (G57T, Leu19Phe) and in B-Raf (V600E) were found in single tumours (Table 2).	B-Raf	tumours	1
64	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	colorectal tumours	1
65	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	tumour	1
66	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	colorectal tumours	1
67	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	tumour	1
68	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	colorectal tumours	1
69	To identify additional K-Ras mutations, and to establish the relative frequencies of individual K-Ras mutations in human colorectal tumours, we used WAVE analysis followed by direct sequencing to screen the same tumour series for mutations in K-Ras exon 3 and exon 4B, the most common exon 4 splice variant	K-Ras	tumour	1
70	To determine the frequencies of the codon 117, 146 and 164 K-Ras mutations and the codon 173 SNP, PCR-RFLP assays were designed to permit rapid screening of blood and tumour DNA (Appendix A)	K-Ras	tumour	1
71	No tumours with codon 19, 117, 146 or 146 mutations had additional K-Ras mutations in codons 12, 13 or 61	K-Ras	tumours	1
72	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and tumour tissues	K-Ras	tumour	1
73	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and tumour tissues	K-Ras	tumour	1
74	To investigate whether altered K-Ras activity could additionally result from gene amplification, a K-Ras gene copy number assay was designed and carried out as described in Materials and Methods and K-Ras copy number compared in normal and tumour tissues	K-Ras	tumour	1
75	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
76	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
77	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
78	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
79	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
80	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
81	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
82	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
83	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
84	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
85	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
86	In total, 2 of the 96 tumour pairs analysed (2.1%) showed tumour-specific copy number increases (Figure 6), one (study code 1264, wt K-Ras) with 4 tumour copies of K-Ras and the other (study code 1233, wt K-Ras) with 27 copies of the K-Ras gene	K-Ras	tumour	1
87	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	tumour	1
88	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	tumour	1
89	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	colorectal tumour	1
90	Figure 7C illustrates a tumour sample (study code 1271) in which the K-Ras gene is not amplified (red fluorescence=green fluorescence), whereas Figure 7D illustrates a colorectal tumour (study code 1264) with K-Ras gene amplification (red fluorescence>green fluorescence)	K-Ras	colorectal tumour	1
91	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)	K-Ras	colorectal tumours	0
92	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)	B-Raf	colorectal tumours	0
93	Recent clinical data has shown a compelling association between K-Ras and B-Raf mutation status and response to EGFR blockade by cetuximab and panitumumab in the treatment of metastatic colorectal tumours (Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008)	EGFR	colorectal tumours	0
94	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	colorectal tumours	0
95	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	tumours	0
96	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	colorectal tumours	0
97	K-Ras mutations in colorectal tumours have been extensively documented, where recent meta analysis of more than 3000 tumours estimates an average K-Ras mutation frequency of 34.8% (Andreyev et al, 2001)	K-Ras	tumours	0
98	Although additional K-Ras mutations have been reported outwith these 'hotspot' codons, to our knowledge, there has been no systematic analysis of K-Ras mutation frequency in human colorectal tumours	K-Ras	colorectal tumours	0
99	Although additional K-Ras mutations have been reported outwith these 'hotspot' codons, to our knowledge, there has been no systematic analysis of K-Ras mutation frequency in human colorectal tumours	K-Ras	colorectal tumours	0
100	Our use of 'WAVE' denaturing HPLC (dHPLC) analysis (Kuklin et al, 1997) allowed us to carry out a rapid, systematic analysis of the entire K-Ras coding sequence to identify colorectal tumours with sequence changes, the nature which were subsequently confirmed by conventional dideoxy sequencing.	K-Ras	colorectal tumours	1
101	Our data clearly demonstrates that K-Ras mutations in human colorectal tumours are likely to be significantly underestimated if only hotspot codons are analysed	K-Ras	colorectal tumours	1
102	Current data from the COSMIC database, which summarises literature data and the ongoing Sanger cancer-genome project describes 29 K-Ras colorectal tumour mutations outwith codons 12, 13 and 61, and more than 11 800 mutations at these hotspot codons (http://www.sanger.ac.uk/genetics/CGP/), but does not describe associated phenotypes	K-Ras	cancer	1
103	Current data from the COSMIC database, which summarises literature data and the ongoing Sanger cancer-genome project describes 29 K-Ras colorectal tumour mutations outwith codons 12, 13 and 61, and more than 11 800 mutations at these hotspot codons (http://www.sanger.ac.uk/genetics/CGP/), but does not describe associated phenotypes	K-Ras	colorectal tumour	1
104	K-Ras codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)	K-Ras	colorectal tumour	0
105	K-Ras codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)	K-Ras	thymic lymphomas	0
106	K-Ras codon 146 mutations have been described in a human colorectal tumour cell line (Higashi et al, 1990), in mice with thymic lymphomas (Sloan et al, 1990) and in a single human colorectal tumour case report (Orita et al, 1991)	K-Ras	colorectal tumour	0
107	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	leukaemia	1
108	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	colorectal cancer	1
109	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	leukaemia	1
110	Consistent with our own data, Tyner et al (2009) reported an oncogenic phenotype associated with the K-Ras 146 mutation in leukaemia and Loupakis et al (2009) have recently reported that a patient with metastatic colorectal cancer with a K-Ras 146 mutation was resistant to cetuximab.	K-Ras	colorectal cancer	1
111	There is only a single report of K-Ras codon 19 mutations in human colorectal tumours (Akagi et al, 2007), in which in vitro elevation of active Ras-GTP levels, anchorage-independent growth and increased tumourigenicity in nude mice was demonstrated	K-Ras	colorectal tumours	1
112	A codon 19 mutation has additionally been described in H-Ras in a human pituitary carcinoma metastases (Pei et al, 1994)	H-Ras	pituitary carcinoma metastases	1
113	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	K-Ras	colorectal tumours	0
114	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	K-Ras	mental retardation Costello syndrome	0
115	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	H-Ras	colorectal tumours	0
116	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	MAPK	colorectal tumours	0
117	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	H-Ras	mental retardation Costello syndrome	0
118	There are two recent reports of codon 117 mutations - the first in K-Ras in human colorectal tumours (Wojcik et al, 2008) and the second in H-Ras, associated with activation of the RAS-MAPK pathway and the mental retardation Costello syndrome (Denayer et al, 2008)	MAPK	mental retardation Costello syndrome	0
119	There are no reports of K-Ras 164 mutations, and mutations at this codon were not identified by Sanger cancer genome project investigators.	K-Ras	cancer	1
120	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	colorectal cancer	1
121	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	K-Ras wt tumours	1
122	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	K-Ras	colorectal cancer	1
123	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	K-Ras	K-Ras wt tumours	1
124	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	colorectal cancer	0
125	Recent clinical data convincingly associates response to anti-EGFR therapies with K-Ras mutation status in patients with metastatic colorectal cancer where, logically, response is preferentially observed in K-Ras wt tumours (Lievre et al, 2006; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Freeman et al, 2008; Karapetis et al, 2008; Ramos et al, 2008; Loupakis et al, 2009; Van Cutsem et al, 2009) which retain the ability to respond to EGFR blockade	EGFR	K-Ras wt tumours	1
126	Our description of K-Ras gene amplification in a subset of wt tumours is of particular interest in this regard as increased K-Ras gene copy number may lead to a more active 'mutation'-like phenotype	K-Ras	tumours	1
127	Our description of K-Ras gene amplification in a subset of wt tumours is of particular interest in this regard as increased K-Ras gene copy number may lead to a more active 'mutation'-like phenotype	K-Ras	tumours	1
128	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP4	pancreatic tumours	0
129	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP4	tumour	0
130	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	K-Ras	pancreatic tumours	0
131	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP6	pancreatic tumours	0
132	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	Raf	pancreatic tumours	0
133	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	K-Ras	tumour	0
134	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	DUSP6	tumour	0
135	Consistent with our own data, DUSP4 expression has previously been shown to be increased in pancreatic tumours with K-Ras mutations (Yip-Schneider et al, 2001) and DUSP6 expression increased in a variety of tumour types with mutations in Ras or Raf pathway genes (Croonquist et al, 2003; Warmka et al, 2004; Bloethner et al, 2005)	Raf	tumour	0
136	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	Igf1	tumour	1
137	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	Vegf	tumour	1
138	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	K-Ras	tumour	1
139	Of particular interest, however, was our observation that certain signalling cascades, including those mediated by Igf1 and Vegf, were differentially activated by cluster 1 and cluster 2 K-Ras mutants, suggesting that not only the presence but the specific molecular characteristics of individual K-Ras mutations may be important determinants of both tumour progression and treatment response	K-Ras	tumour	1
140	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	glucose deprivation	1
141	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	GLUT-1	glucose deprivation	1
142	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	glucose deprivation	1
143	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1
144	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1
145	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	GLUT-1	tumours	1
146	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1
147	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	GLUT-1	tumours	1
148	For example, recent data suggests that glucose deprivation can promote the acquisition of K-Ras mutations in human tumours and reports upregulation of the glucose transporter GLUT-1 in K-Ras mutant tumours (Yun et al, 2009)	K-Ras	tumours	1
149	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	K-Ras	van Krieken	0
150	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	K-Ras	K-Ras tumour	0
151	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	EGFR	van Krieken	0
152	Current clinical data is sufficiently compelling that K-Ras mutation testing to facilitate the selection of patients most likely to benefit from anti-EGFR therapy is increasingly recommended in clinical practise (McNeill, 2008; van Krieken and Tol, 2009), and has resulted in a recent formal recommendation from the National Comprehensive Cancer Network that patients with K-Ras tumour mutations should not be treated with cetuximab or panitumumab (McNeill, 2008)	EGFR	K-Ras tumour	0
153	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in colorectal tumours should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.	K-Ras	colorectal tumours	1
154	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in colorectal tumours should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.	K-Ras	colorectal tumours	1
155	Although the clinical implications of non-hotspot K-Ras mutations requires further validation both as prognostic markers and therapeutic targets, our data suggests that future analysis of K-Ras mutations and quantitation of mutation burden in colorectal tumours should not be limited to previously described mutation hotspots and should additionally consider the unique molecular signatures associated with individual K-Ras mutations.	K-Ras	colorectal tumours	1
156	Characterization of a novel oncogenic K-ras mutation in colon cancer	K-ras	colon cancer	1
157	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies	RAF	colorectal cancers	1
158	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies	epidermal growth factor receptor	colorectal cancers	1
159	Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines	B-RAF	melanoma	1
160	Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines	N-RAS	melanoma	1
161	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	K-ras	APC	1
162	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	K-ras	colorectal carcinoma	1
163	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	p53	APC	1
164	The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma	p53	colorectal carcinoma	1
165	Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells	IL-6	myeloma	1
166	Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells	N-ras	myeloma	1
167	Mutations of the BRAF gene in human cancer	BRAF	cancer	1
168	Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation	HRAS	Costello syndrome	1
169	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer	BRAF	colorectal cancer	1
170	Recurrent KRAS codon 146 mutations in human colorectal cancer	KRAS	colorectal cancer	1
171	K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy	K-Ras	colorectal cancer	1
172	Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone	K-ras	colorectal cancer	1
173	Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes	RUNX1	chronic myelomonocytic leukemia	1
174	K-ras mutations and benefit from cetuximab in advanced colorectal cancer	K-ras	colorectal cancer	1
175	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab	epiregulin	colorectal cancer	1
176	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab	amphiregulin	colorectal cancer	1
177	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab	K-ras	colorectal cancer	1
178	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	K-ras	APC	1
179	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	p53	APC	1
180	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	K-ras	colorectal adenocarcinomas	1
181	Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas	p53	colorectal adenocarcinomas	1
182	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer	KRAS	colorectal cancer	1
183	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer	KRAS	colorectal cancer	1
184	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer	BRAF	colorectal cancer	1
185	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer	KRAS	colorectal cancer	1
186	K-Ras mutations are changingpractice in advanced colorectal cancer	K-Ras	colorectal cancer	1
187	Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer	K-ras	colon cancer	1
188	A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction	K-ras	colorectal cancer	1
189	H-ras mutations in human pituitary carcinoma metastases	H-ras	pituitary carcinoma metastases	1
190	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer	K-ras	colorectal cancer	1
191	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer	epidermal growth factor receptor	colorectal cancer	1
192	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	Kirsten-ras	APC	1
193	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	p53	APC	1
194	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	Kirsten-ras	colorectal cancer	1
195	Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer	p53	colorectal cancer	1
196	Setting future standards for KRAS testing in colorectal cancer	KRAS	colorectal cancer	1
197	Mitogen-activated protein kinase phosphatase-3 is a tumor promoter target in initiated cells that express oncogenic Ras	Mitogen-activated protein kinase phosphatase-3	tumor	1
198	Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer	K-Ras	colorectal cancer	1
199	KRAS mutation profile in colorectal carcinoma and novel mutation-internal tandem duplication in KRAS	KRAS	colorectal carcinoma	1
200	Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2	K-ras	Pancreatic tumor	1
201	Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2	ERK	Pancreatic tumor	1
202	Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2	MEK	Pancreatic tumor	1
203	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells	KRAS	Glucose deprivation	1
204	Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells	KRAS	tumor	1
205	Active Ras, where tumour-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.	RAF	tumour	1
206	Active Ras, where tumour-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.	MEK	tumour	1
207	Active Ras, where tumour-specific mutations lock Ras in the GTP-bound conformation, stimulates the RAS-RAF-MEK-ERK-MAP kinase signalling pathway.	ERK	tumour	1
208	A novel K-Ras gene copy number assay was designed as described in Materials and Methods and used to screen genomic DNA samples extracted from 96 paired normal (N) and colorectal tumour (T) tissues	K-Ras	colorectal tumour	1
209	Representative colorectal tumour sections (C) without and (D) with a K-Ras gene amplification are illustrated.	K-Ras	colorectal tumour	1
